Back to search

Article

Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting System

2026-08-26

Abstract excerpt

<title>Abstract</title> <p>Background. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying as an on-target effect. Independent FAERS analyses have reported that GLP-1 RAs account for a large share of impaired-gastric-emptying (IGE) reports (Huang et al., 2025; Tu et al., 2026). We sought to reproduce this signal at the active-substance level using a transparent, fully reproducible pipelin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cb810e4a-a8d0-557c-b7b2-0914d7d50de9
DOI
10.21203/rs.3.rs-9818000/v3
Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemDOI 10.21203/rs.3.rs-9818000/v3
Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Adverse event analysis and signal detection of calcitonin gene-related peptide inhibitors using the FDA Adverse Event Reporting System databaseSemantic proximity
Gastrointestinal adverse events associated with Riociguat: A pharmacovigilance study based on FDA adverse event reporting systemSemantic proximity
Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES DatabaseSemantic proximity
Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity
The Adverse Event Atlas and Signal Consensus Index: A Multi-Source Pharmacovigilance PlatformSemantic proximity
Drug-associated acute pancreatitis in paediatric versus adult reports: a disproportionality analysis of FAERSSemantic proximity
Infliximab-associated Gastrointestinal Obstruction: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (2004-2024)Semantic proximity
Neurosensory Risk After Semaglutide or Tirzepatide Is Lower Than Matched Antidiabetic and Bariatric Surgery Cohorts and Tracks Glycemic BurdenSemantic proximity
Distinct glycaemic safety reporting patterns for alpelisib and capivasertib: a disproportionality analysis of the FAERS databaseSemantic proximity
Select a neighboring publication to make it the new centre.